CHMP Approvals, Aligned Pathway, JCA Scale-up

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: CHMP May approvals, MHRA-NICE aligned pathway, Tovorafenib JCA, valproate review, and JCA scale-up. Let's get into it.

MarcusEMA's CHMP met in May, granting eight new approvals. Notably, one was a significant rare disease treatment. This aligns with the broader trend of increased attention to rare diseases in regulatory decisions. The approval pace remains steady, but the focus on rare conditions is a clear signal for HEOR teams to prepare robust real-world evidence strategies.

SaraTrue, but let's not overlook the commercial implications. Rare disease treatments often come with high prices and small populations. The challenge is demonstrating cost-effectiveness in such settings. HTA bodies are increasingly demanding innovative pricing models, like outcomes-based agreements, which require even more sophisticated evidence generation. The regulatory approval is just the first step; the real battle is in value demonstration.

MarcusThe MHRA and NICE have issued their first joint guidance under the aligned pathway. This is for a novel oncology therapy. The goal is to streamline regulatory and HTA processes, reducing duplication and accelerating patient access. A significant step towards convergence.

SaraConvergence? That's a bold claim. The guidance document itself highlights several methodological divergences. For instance, the MHRA focuses on safety and efficacy, while NICE demands cost-effectiveness. How can they be aligned when the core requirements are fundamentally different? This feels more like parallel processes with a shared deadline than true alignment. We need to see if this actually reduces the burden on manufacturers or just creates a new layer of complexity.

MarcusBut the intention is clear. By starting early, they can address both sets of requirements simultaneously. The first case is in oncology, where the stakes are high and the evidence is often limited. This could be a model for other therapeutic areas. The alternative is the current disjointed approach, which leads to delays and uncertainty.

MarcusThe EU Joint Clinical Assessment published its second report on tovorafenib, a pediatric oncology treatment. The report highlights methodological challenges in assessing pediatric cancer therapies, particularly in using adult data to extrapolate efficacy. This underscores the need for more pediatric-specific trial designs and endpoints in HTA submissions.

SaraExactly. The JCA is pointing out what we've known for years: pediatric oncology trials are logistically and ethically complex, leading to smaller sample sizes and surrogate endpoints. But HTA bodies are still applying the same cost-effectiveness thresholds as for adult treatments. This creates a mismatch. The report should be a call to action for adaptive trial designs and more flexible value frameworks for pediatric populations, but I'm not seeing that shift yet.

MarcusPRAC concluded its safety review on valproate, specifically addressing paternal exposure. The conclusions reinforce existing pharmacovigilance methodologies, emphasizing the importance of long-term follow-up and comprehensive risk communication. This sets a precedent for how other reproductive safety issues will be handled.

SaraPrecedent? I see it more as a reminder of the limitations of current pharmacovigilance systems. The review took years, and the conclusions are still based on observational data. For newer, more targeted therapies, we need proactive safety monitoring, not just reactive reviews. The pharmaceutical industry should be investing in real-world data platforms that can detect these signals earlier, rather than waiting for PRAC to initiate a review. This is a call for more integrated safety and evidence generation.

MarcusThe EU Joint Clinical Assessment is scaling up to 50 assessments annually. This expansion is necessary to handle the increasing volume of new medicines and medical devices. However, it also brings capacity planning challenges. The JCA is now recognizing these bottlenecks and is working on solutions, but the timeline remains tight.

SaraFifty assessments? That's ambitious, but I'm concerned about the quality. The JCA already struggles with consistency across assessments. Scaling up without a proportional increase in resources or expertise could lead to variability in the quality of the reports. Manufacturers need predictability and consistency in the HTA process. If the JCA becomes a bottleneck due to capacity issues, it might actually slow down access, not speed it up. We need more than just numbers; we need a sustainable model.

MarcusThat's all for today. A busy week in HEOR and market access.

SaraIndeed. From regulatory approvals to methodological challenges, the landscape is evolving rapidly.

MarcusStay tuned for more insights.

SaraBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.